What is NuSkin Enterprises's impairment of strategic investments?

NuSkin Enterprises (NUS) reported impairment of strategic investments of $0 in Q1 2026.

How has NuSkin Enterprises's impairment of strategic investments changed year-over-year?

NuSkin Enterprises's impairment of strategic investments decreased by 100.0% year-over-year, from $28.08M to $0.

USANA Health SciencesUSNA

$0—

Revenue$320.6M-12.0%

Gross profit$214.5M-13.2%

Operating income$4.0M+141%

Net income$1.8M-98.3%

EPS (diluted)$0.04-98.1%

Cash & equivalents$198.7M-2.5%

Total debt$303.6M-8.2%

Total equity$794.1M+5.3%

Total assets$1.4B-1.1%

Operating cash flow-$3.9M-1,107%

CapEx$13.7M+1.0%

Free cash flow-$17.6M-33.6%

Market cap$256.35M-38.2%

Reported directly by NuSkin Enterprises in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

What is NuSkin Enterprises's impairment of strategic investments?: NuSkin Enterprises (NUS) reported impairment of strategic investments of $0 in Q1 2026.
How has NuSkin Enterprises's impairment of strategic investments changed year-over-year?: NuSkin Enterprises's impairment of strategic investments decreased by 100.0% year-over-year, from $28.08M to $0.